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Objectives The aim of this study was to compare, in a large all-comers registry, major adverse car-
diac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with ﬁrst-
generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected
left main coronary artery (ULMCA) stenosis.
Background Percutaneous coronary intervention with DES implantation in ULMCA has been shown
to be a feasible and safe approach at midterm clinical follow-up.
Methods All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were
analyzed in this multinational registry. A propensity score analysis was performed to adjust for base-
line differences in the overall cohort.
Results In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At
1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in
the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI)
(adjusted hazard ratio [HR]: 1.11; 95% conﬁdence interval [CI]: 0.85 to 1.42; p  0.47), mortality (ad-
usted HR: 1.16; 95% CI: 0.87 to 1.55; p  0.32), or composite endpoint of death and MI (adjusted
HR: 1.25; 95% CI: 0.95 to 1.64; p  0.11). An advantage of CABG over PCI was observed in the com-
posite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p  0.0001), driven
exclusively by the higher incidence of target vessel revascularization with PCI.
Conclusions In our multinational all-comers registry, no difference was observed in the occurrence of death,
cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in
the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI. (J Am
Coll Cardiol Intv 2012;5:718–27) © 2012 by the American College of Cardiology Foundation
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719Percutaneous coronary intervention (PCI) for unprotected
left main coronary artery (ULMCA) lesions has a Class IIb
indication, in high-risk surgical patients, according to recent
guidelines (1). In this challenging subset of patients, PCI
with drug-eluting stent (DES) implantation has been
shown to be a feasible and safe approach at midterm clinical
follow-up (2–10). Recently, results from multicenter regis-
tries have reported favorable outcomes at 3-year clinical
follow-up (11–18). Moreover, single-center registries eval-
uating PCI with DES versus coronary artery bypass grafting
(CABG) in this subset of patients have shown encouraging
and comparable outcomes between these 2 treatment options,
sustained up to 5 years of clinical follow-up (13). The noninfe-
riority of PCI as compared with CABG in major adverse
cardiac and cerebrovascular events (MACCE) at 12 months in
this subset has been reported in the randomized SYNTAX
(Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery) trial (19). Additionally,
improved left ventricular ejection fraction (LVEF) in the
PCI group when compared with CABG at 1-year follow-up
was stated in the randomized LEMANS (Study of Unpro-
tected Left Main Stenting Versus Bypass Surgery) (20). The
aim of the present study was to evaluate the long-term
clinical outcomes of ULMCA PCI with DES in a “real-
world” setting and compare these with the results of those
undergoing CABG.
Methods
Consecutive “all comers” with ULMCA stenosis treated
with PCI and “first generation” DES (sirolimus- and
paclitaxel-eluting stents) implantation or CABG between
April 2002 and April 2006 in 14 centers were retrospectively
analyzed in this multinational registry. In all institutions,
patients were evaluated by both interventional cardiologists
and cardiac surgeons, and the decision to perform PCI or
CABG was made on the basis of: 1) hemodynamic conditions;
2) lesion characteristics; 3) vessel size; 4) the presence of
comorbidities; 5) quality of arterial and/or venous conduits
for grafting; and 6) patient and/or referring physician
preferences.
In all cases, the selected revascularization approach
seemed suitable to guarantee complete revascularization. All
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Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
CK  creatine kinase
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
EuroSCORE  European
System for Cardiac Operative
Risk Evaluation
HR  hazard ratio
IABP  intra-aortic balloon
pump
IQR  interquartile range
IVUS  intravascular
ultrasound
LVEF  left ventricular
ejection fraction
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary arteryccepted March 29, 2012.
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720due to a cardiac cause (e.g., MI, low-output failure, fatal
arrhythmia), procedure-related deaths, and death of un-
known cause. Target lesion revascularization was defined as
any repeat intervention of the target lesion or other com-
plication of the target lesion. The target lesion was defined
as the treated segment 5 mm proximally to the stent and 5
mm distally to the stent; TVR was defined as any repeat
intervention of any segment of the target vessel, defined as
the entire major coronary vessel proximal and distal to the
target lesion, including upstream and downstream branches
and the target lesion itself. Cerebrovascular accidents were
defined as stroke, transient ischemic attacks, and reversible
ischemic neurological deficits adjudicated by a neurologist
and confirmed by computed tomography scanning.
In-hospital non–Q-wave MI was defined as the elevation
of the serum creatine kinase (CK) isoenzyme myocardial
band that was 3 the upper limit of normal in the PCI
roup and 5 the upper limit of normal in the CABG
roup, in the absence of new pathological Q waves (22). In
his analysis were included as cumulative MI: 1) all Q-wave
I that occurred during hospital stay and follow-up; and
) all spontaneous MI occurring after hospital discharge.
-wave MI was defined as the development of new path-
logical Q waves in 2 or more contiguous leads with or
ithout CK or CK-myocardial band levels elevated above
ormal. Spontaneous MI was defined as the occurrence
fter hospital discharge of any value of troponin and/or
K-myocardial band greater than the upper limit of normal
f associated with clinical and/or electrocardiogram change.
ajor adverse cardiac and cerebrovascular event was defined
s the composite endpoint of death, CVA, MI, and TVR.
The European System for Cardiac Operative Risk Evalua-
ion (EuroSCORE)—which is based on patient-, cardiac-,
nd operation-related factors—was used to stratify the risk of
eath at 30 days.
Diagnostic angiograms were scored according to the
YNTAX score algorithm at the site laboratory (23).
atients were divided into low score (0 to 22), mid score (23
o 32), and high score (32) groups.
Study endpoints. The primary study endpoint was the
incidence of death (overall and cardiac), CVA, and MI at
long-term follow-up. The secondary study endpoints were
the occurrence of death (overall and cardiac), death and MI,
MACCE, and TVR.
Statistical analysis. Data are presented as percentages and
ean  SD. In general, differences in proportions were
ested with chi-square test or Fisher exact test, and differ-
nces in continuous variables were tested with a Student
test. Cumulative event curves were generated with the
aplan-Meier method and compared by the log-rank test.
ecause of the nonrandomized nature of the study, a
ropensity score analysis was performed to minimize any
election bias due to the differences in clinical characteristics
etween the 2 treatment groups. Briefly, for each patient aropensity score indicating the likelihood of having PCI
as calculated by the use of a nonparsimonious multivari-
ble logistic regression. A propensity score, indicating the
redicted probability of receiving a specific treatment con-
itional on the observed covariates, was then calculated
rom the logistic equation for each patient. Variables in-
luded in the logistic regression model to calculate the
ropensity score were age, sex, diabetes, smoking, family
istory of coronary artery disease, unstable angina, acute
yocardial infarction, chronic kidney disease, LVEF, pre-
ious CABG, previous PCI, multivessel disease, and con-
omitant right coronary artery disease. The C-statistic was
.78, and the Hosmer-Lemeshow test p value was 0.38,
onfirming good discrimination and calibration of the
ropensity score model. The individual propensity score was
ncorporated into Cox proportional hazards regression
odels as a covariate as well as treatment group to calculate
he adjusted hazard ratio (HR). Also, the propensity scores
ere grouped into quintiles, and HR was compared across
uintiles. In addition, to reduce the effect of treatment-
election bias and potential confounding in this observa-
ional study, we performed rigorous adjustment for signifi-
ant differences in the baseline characteristics of patients
ith propensity-score matching using the following al-
orithm: 1:1 optimal match with a 0.03 caliper and no
eplacement. Clinical outcomes in the matched population
ere analyzed with Cox proportional hazards regression
tratified on matched-pairs. Multivariable Cox proportional-
azards regression modeling was performed to determine
he independent predictors of the primary endpoint (death,
VA, or MI), MACCE, and death with purposeful selec-
ion of covariates. Variables associated at univariate analysis
all with a p value 0.1) and those judged to be of clinical
mportance from previous published reports were eligible for
nclusion into the multivariable model-building process.
he goodness of fit of the Cox multivariable model was
ssessed with the Grønnesby-Borgan-May test.
Results are reported as HR with associated 95% confi-
ence interval (CI) and p value. All statistical analysis was
erformed with Stata (version 9.0, Stata Corporation, Col-
ege Station, Texas).
esults
The baseline clinical characteristics are summarized in
Table 1. In this “all comers” registry, 2,775 patients were
included: 1,874 underwent PCI with implantation of “first-
generation” DES, and 901 underwent CABG. Among the
overall population, 2,187 patients were treated electively:
1,445 patients were treated with PCI, and 742 were treated
with CABG. In the PCI group, 893 (47.6%) patients had
paclitaxel-eluting stent implantation, and 893 (44.7%) had
sirolimus-eluting stent implantation. Patients treated with
PCI were more frequently male (73.9% vs. 63.6%; p 0.01)
0
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721and had a family history of coronary artery disease (29.1%
vs. 25.3%; p  0.038), chronic kidney disease (7.3% vs.
4.1%; p  0.01), previous CABG (10.7% vs. 2.7%; p 
.01), and/or PCI (24.8% vs. 13.7%; p  0.01) and
resented with acute coronary syndromes (non–ST-
egment elevation myocardial infarction 11.6% vs. 11.1%
nd ST-segment elevation myocardial infarction 2.9% vs.
.8%). More patients treated with CABG had multivessel
isease (94.2% vs. 79.8%; p  0.01) and higher SYNTAX
scores (38.9 13.2 vs. 28.6 14.3; p 0.01). All the other
baseline variables were similar.
The lesion and procedural characteristics are illustrated in
Table 2. An intra-aortic balloon pump was more frequently
used during PCI (7.0% vs. 3.4%; p  0.01), most likely a
reflection of the higher occurrence of emergency procedures
in this group. Emergency procedures were performed in 429
(22.8%) patients in the PCI group versus 158 (17.5%) in the
CABG group. A distal location was present in 1,130
(60.3%) of the patients treated with PCI: 745 (65.9%) were
bifurcation lesions. Both branches were stented in 487
(43.1%) of the distal locations. An IVUS was performed in
only 33.1% of the cases, varying considerably among the
centers and reflecting the common practice during the study
period.
Hospital and long-term MACCE. Periprocedural MI occurred
Table 1. Baseline Clinical Characteristics
PCI Overall
(N  1,874)
CABG Overall
(N  900) p Value
Male 1,385 (73.9) 572 (63.6) 0.01
Age, yrs 65.8 11.5 66.5 9.8 0.24
Family history of CAD 546 (29.1) 228 (25.3) 0.038
Hypertension 1,200 (64.0) 609 (67.7) 0.061
Dyslipidemia 1,159 (61.8) 582 (64.7) 0.15
Smokers 847 (45.2) 384 (42.7) 0.22
Diabetes 520 (27.7) 306 (34.0) 0.01
IDDM 115 (6.1) 65 (7.2)
NIDDM 405 (21.6) 241 (26.8)
Chronic kidney disease 137 (7.3) 37 (4.1) 0.01
Clinical presentation
Stable angina/silent
ischemia
988 (52.7) 317 (35.2) 0.01
Unstable angina 614 (32.8) 476 (52.9) 0.01
NSTEMI 218 (11.6) 100 (11.1) 0.01
STEMI 54 (2.9) 7 (0.8) 0.01
Previous CABG 201 (10.7) 24 (2.7) 0.01
Previous PCI 465 (24.8) 123 (13.7) 0.01
LVEF 53.8 12 53.3 11.5 0.29
EuroSCORE 4.9 3.6 5.1 2.6 0.17
Values are n (%) or mean SD.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; IDDM  insulin-
dependent diabetes mellitus; LVEF left ventricular ejection fraction; NIDDM noninsulin-
dependent diabetes mellitus; NSTEMI  non–ST-segment elevation myocardial infarction;
PCI percutaneous coronary intervention; STEMI ST-segment elevationmyocardial infarction.in 88 (4.7%) of the patients treated with PCI versus 213Table 2. Angiographic and Procedural Characteristics
PCI Overall
(N  1,874)
CABG Overall
(N  900) p Value
Multivessel disease 1,495 (79.8) 848 (94.2) 0.01
LAD/CX disease 1,211 (64.6) 758 (84.2) 0.037
RCA disease 684 (36.5) 627 (69.7)
SYNTAX score 28.6 14.3 38.9 13.2 0.01
Lesion location
Ostial/shaft 744 (39.7) 374 (41.6) 0.23
Distal 1,130 (60.3) 526 (58.4) 0.36
True bifurcation 745 (39.8) 91 (10.1) 0.01
Pre-dilation 821 (43.8)
Atherectomy 25 (1.3)
Rotablator 28 (1.5)
Cutting balloon 167 (8.9)
IABP 131 (7.0) 31 (3.4) 0.01
IVUS 621 (33.1)
IVUS guided procedure 161 (8.6)
IVUS controlled procedure 460 (24.5)
DES type (for LM lesion)
Cypher 938
Taxus 893
Endeavor 4
Xience V 43
Mean stent diameter 3.44 0.54
Mean stent length 22.6 19.4
2-stent strategy 487 (43.1)
Stenting technique
Crush 196 (10.5)
Mini-crush 53 (2.8)
Culotte 40 (2.1)
T stenting 135 (7.2)
V stenting 63 (3.4)
Post-dilation 867 (46.3)
Max balloon diameter 3.6 0.58
Max pressure (atm) 15.7 3.8
Final kissing balloon 820 (43.8)
GP IIb/IIIa
Abciximab 201 (10.7)
Eptiﬁbatide 29 (1.5)
Tiroﬁban 206 (11.0)
Bivalirudin 47 (2.5)
Vessels treated 1.4 0.84 2.1 0.9 0.01
Lesions treated 1.5 0.99
Stent/lesion ratio 1.28 0.65
CABG beating heart 126 (14.0)
Mean arterial graft 2 1.02
Mean venous graft 1.7 1.2
Graft/patient ratio 3.7 1.6
Complete revascularization 840 (93.3)
Unintentional incomplete 33 (3.7)
Mean hospital stay (days) 12.5 11.2
Values are n (%), n, or mean SD.
CX  circumflex artery; DES  drug-eluting stent(s); GP  glycoprotein; IABP  intra-aortic
balloon pump; IVUS intravascular ultrasound; LAD left anterior descending artery; LM left
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722(23.6%) with CABG. Of these, Q-wave MI was detected in
only 11 patients with PCI versus 15 in the CABG group.
In-hospital death occurred in 41 (2.2%) patients in the PCI
group versus 29 (3.2%) of the CABG group: cardiac death
was adjudicated in 33 (1.7%) patients in the PCI versus 20
(2.2%) in the CABG group. A periprocedural CVA oc-
curred in 4 (0.2%) patients treated with PCI and in 12
(1.3%) of those undergoing CABG. Target vessel revascu-
larization was performed in 15 (0.8%) patients treated with
PCI versus 3 (0.3%) patients treated with CABG.
Clinical follow-up was obtained overall in 95% of the
patients (2-year follow-up was available in 90% of PCI
patients and in 87% of CABG patients).
At a median follow-up of 1,295 (interquartile range
[IQR]: 928 to 1,713) days, 103 patients (11.4%) in the
CABG group versus 264 (14.1%) in the PCI group died.
Among them, 61 (6.8%) were adjudicated as cardiac deaths
in the CABG cohort and 140 (7.5%) in the PCI group.
During follow-up, 33 (4.0%) patients in the CABG arm
experienced an MI compared with 75 (3.7%) in the PCI
group. Target vessel revascularization was performed in 290
(15.5%) of the patients treated with PCI versus 44 (5.2%)
with CABG. Of these, TLR occurred in 192 (10.2%) in the
PCI versus 36 (4.3%) in the CABG group. Cerebrovascular
accident occurred in 25 patients (2.9%) in the CABG group
and in 30 (1.6%) in the PCI group. Definite ST occurred in
20 (1.06%) patients: 6 subacutely, 9 late, and 5 very late.
Probable ST was adjudicated in 12 (0.6%) patients, and
possible ST was adjudicated in 8 (0.4%) patients. In-
hospital and follow-up MACCE are illustrated in Table 3.
Study endpoints. At a median of 1,295 (IQR 928 to 1,713)
days of clinical follow-up, no difference in the primary
Table 3. Cumulative Incidence of MACCE in the Overall Population
PCI Overall
(N  1,874)
CABG Overall
(N  900)
In-hospital events
Cardiac death 33 (1.7) 20 (2.2)
Noncardiac death 8 (0.5) 9 (1)
Myocardial infarction 88 (4.7) 213 (23.6)
Target lesion revascularization 0 (0) 0 (0)
Target vessel revascularization 15 (0.8) 3 (0.3)
Cerebrovascular accident 4 (0.2) 12 (1.3)
MACCE 148 (7.9) 257 (28.4)
Events at follow-up
Cardiac death 140 (7.5) 61 (6.8)
Noncardiac death 124 (6.6) 42 (4.6)
Myocardial infarction 75 (3.7) 33 (4)
Target lesion revascularization 192 (10.2) 36 (4.3)
Target vessel revascularization 290 (15.5) 44 (5.2)
Cerebrovascular accident 30 (1.6) 25 (2.9)
MACCE 659 (34.9) 205 (23.5)
Values are n (%).MACCEmajor adverse cardiac and cerebrovascular events; other abbreviations as in Table 1.endpoint of death, CVA, and MI was observed (17.6% PCI
vs. 16.9% CABG; unadjusted HR: 1.11; 95% CI: 0.89 to
1.36; p  0.38; adjusted HR: 1.11; 95% CI: 0.85 to 1.42;
p  0.47). Furthermore, no significant differences were
found in mortality (unadjusted HR: 1.29; 95% CI: 1.01 to
1.65; p  0.04; adjusted HR: 1.16; 95% CI: 0.87 to 1.55;
p  0.32) and the composite endpoint of death and MI
(16.7% in PCI vs. 13.9% in CABG; unadjusted HR: 1.22;
95% CI: 0.98 to 1.53; p 0.07; adjusted HR: 1.25; 95% CI:
0.95 to 1.64; p  0.11).
An advantage of CABG over PCI was observed in the
composite secondary endpoint of MACCE (30.3% in the
PCI group vs. 20.1% in the CABG group; unadjusted HR:
1.58; 95% CI: 1.32 to 1.90; p  0.0001; adjusted HR: 1.64;
95% CI: 1.33 to 2.03; p  0.0001), driven by the benefit of
CABG in terms of TVR (unadjusted HR: 3.65; 95% CI:
2.57 to 5.19; p  0.0001; adjusted HR: 3.51; 95% CI: 2.40
to 5.13; p  0.0001) as well as TLR (unadjusted HR: 2.78;
95% CI: 1.89 to 4.10; p  0.0001; adjusted HR: 2.65; 95%
CI: 1.73 to 4.04; p  0.0001). No differences in the study
endpoints were observed in the elective population com-
pared with overall results. Additionally, when the propensity
score analysis was performed according to quintiles, the
results were consistent with the overall analysis. Kaplan-
Meier survival curves for the primary endpoint of death, MI,
and CVA; death; death or MI; and MACCE are illustrated
in Figure 1.
Multivariate analysis for predictors of primary and secondary
study endpoints. At Cox regression multivariable analysis,
age (1.03; 95% CI: 1.00 to 1.04; p  0.009), EuroSCORE
(1.06; 95% CI: 1.01 to 1.10; p  0.02), SYNTAX score
(1.02; 95% CI: 1.01 to 1.03; p  0.0001), emergency
procedures (0.68; 95% CI: 0.48 to 0.95; p 0.02), and need
or intra-aortic balloon pump (IABP) (1.85, 95% CI: 1.27
o 2.68; p  0.001) were found to be predictors of the
omposite primary endpoint of death, MI, and CVA
Table 4).
Predictors of death were age (1.03; 95% CI: 1.01 to 1.05;
 0.001), LVEF (0.98, 95% CI: 0.97 to 0.99; p  0.02),
SYNTAX score (1.03, 95% CI: 1.02 to 1.04; p  0.0001),
presentation with acute MI (1.62; 95% CI: 1.03 to 2.53;
p  0.04), and the need for IABP support (2.0; 95% CI:
1.35 to 2.97; p  0.001).
Predictors of MACCE were PCI (1.38; 95% CI: 1.01 to
1.89; p 0.046), EuroSCORE (1.05; 95% CI: 1.02 to 1.09;
p  0.005), SYNTAX score (1.01; 95% CI: 1.01 to 1.02;
p  0.0001), need for IABP support (2.06; 95% CI: 1.52 to
2.79; p  0.0001), and distal ULMCA disease (1.34; 95%
CI: 1.04 to 1.72; p  0.02).
Propensity matched analysis. After propensity-score match-
ing was performed, there were 602 matched pairs of patients
in both treatment groups. Baseline clinical and lesion
characteristics of the matched groups are shown in the Online
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723Appendix. For the 602 matched pairs, there was no significant
difference between the PCI and CABG groups in the risk of the
primary endpoint of death, CVA, and MI (HR: 0.91; 95% CI:
0.66 to 1.26; p  0.57). Furthermore, no significant differences
were found in mortality (HR: 1.0; 95% CI: 0.70 to 1.43; p 1.0)
Figure 1. Freedom From Cardiac and Cerebrovascular Events in PCI Versus
Freedom from cardiac death, myocardial infarction (MI), and cerebrovascular a
cardiac and cerebrovascular events (MACCE) (D) after percutaneous coronary i
(blue line) in the overall population. Patients at risk at different times are rep
Table 4. Predictors of the Primary Endpoint at Cox Multivariable Analysis
HR 95% CI p Value
PCI vs. CABG 0.98 0.67–1.44 0.94
Age 1.02 1.00–1.04 0.009
LVEF 0.99 0.97–1.00 0.06
EuroSCORE 1.06 1.01–1.10 0.02
SYNTAX score 1.02 1.01–1.03 0.0001
Elective 0.68 0.48–0.95 0.02
IABP 1.85 1.27–2.68 0.001
Adjusted for presence of sex and chronic kidney disease.CI confidence interval; HR hazard ratio; other abbreviations as in Tables 1 and 2.nd the composite endpoint of death and MI (HR: 1.02; 95% CI:
.72 to 1.42; p  0.93).
An advantage of CABG over PCI was observed in the
omposite secondary endpoint of MACCE (HR: 1.35; 95%
I: 1.03 to 1.76; p  0.03), driven by the benefit of CABG
n terms of TVR (HR: 2.96; 95% CI: 1.84 to 4.74; p 
.0001) as well as TLR (HR: 2.0; 95% CI: 1.18 to 3.38;
 0.009).
Kaplan-Meier survival curves for the primary endpoint of
eath, MI, or CVA; death; death or MI; and MACCE in
he propensity score matched groups are illustrated in
igure 2.
iscussion
The main findings of this large multicenter, multinational,
“all comers” registry are: 1) no difference was found at a
G in the Overall Population
ts (CVA) (A); from death and MI (B); from death (C); and from major adverse
ntion (PCI) (green line) versus coronary artery bypass grafting (CABG)
below each graph.CAB
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724occurrence of the primary endpoint (death, MI, and CVA)
between PCI with DES implantation and CABG for
ULMCA disease both in the propensity analysis as well as
in the propensity matched analysis; 2) there is still an
advantage of CABG over PCI in terms of MACCE that is
exclusively driven by a lower incidence of repeat revascular-
ization; 3) PCI in this particular subset of patients can be
considered a safe procedure, and this is testified to by the
low occurrence of ST and mortality despite the “all comers”
design; and 4) age, LVEF, EuroSCORE, SYNTAX score,
emergency procedures, and need for hemodynamic support
were found to be correlated to the occurrence of death, MI,
and CVA.
Encouraging long-term results have been reported for
PCI with DES implantation in this particular lesion subset
(2–8,10,24). Moreover, several observational, nonrandom-
ized registries (5,11,22) have shown no difference in the
Figure 2. Freedom From Cardiac and Cerebrovascular Events in PCI Versus
Freedom from cardiac death, myocardial infarction (MI), and cerebrovascular a
cardiac and cerebrovascular events (MACCE) (D) after percutaneous coronary i
(blue line) in the propensity score matched groups. Patients at risk at differenoccurrence of MACCE between patients treated with DEScompared with the ones treated with CABG in this subset
of patients up to 5 years of clinical follow-up (13,16).
Promising results were reported from randomized trials
comparing first-generation DES versus CABG (19,25,26).
In the SYNTAX trial, patients were stratified according
to the presence of ULMCA disease (19) and randomized
to CABG (n  348) or PCI with paclitaxel-eluting stents
n  357). In the ULMCA subgroup, MACCE at 12
onths was comparable between PCI and CABG (13.7%
s. 15.8%; p  0.44). Moreover, although the rate of
epeat revascularization among patients with ULMCA
isease was significantly higher in the PCI group (11.8%,
s. 6.5%; p  0.02), this result was offset by a significantly
igher rate of stroke in the CABG subgroup (2.7%, vs.
.3%; p  0.01) (19). The results have been recently
confirmed at 4 years (presented November 7, 2011 at the
Transcatheter Therapeutics Scientific Sessions, San Francisco,
G in the Propensity Score-Matched Groups
ts (CVA) (A); from death and MI (B); from death (C); and from major adverse
ntion (PCI) (green line) versus coronary artery bypass grafting (CABG)
s are reported below each graph.CAB
cciden
nterveCalifornia).
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725It is important to consider that SYNTAX, PRECOMBAT
(Randomized Comparison of Bypass Surgery Versus An-
gioplasty Using Sirolimus-Eluting Stent in Patients With
Left Main Coronary Artery Disease), and also MAIN
COMPARE (Revascularization for Unprotected Left Main
Coronary Artery Stenosis: Comparison of Percutaneous
Coronary Angioplasty versus Surgical Revascularization)
(19,25,27) do not have an “all-comers” design, and patients
with ACS and cardiogenic shock were excluded. Our
registry does have an “all comers” design; no patients were
excluded, including those admitted with ACS, non-ST-
segment elevation myocardial infarction, and ST-segment
elevation myocardial infarction. Moreover, in this study—
which to the best of our knowledge is the largest thus
far—only patients exclusively treated with DES were in-
cluded (n  1,874): of these 1,445 were treated electively,
ompared with 901 patients treated in this way by CABG.
Because of the nonrandomized nature of our study, an
djusted analysis with the propensity score was performed to
ake into account the differences in baseline clinical charac-
eristics. At a median clinical follow-up of 1,295 (IQR 928
o 1,713) days, no difference was observed in the primary
ndpoint of death, CVA, and MI. Similarly, no significant
ifferences were found in mortality and the composite
ndpoint of death and MI. Conversely, the advantage of
ABG over PCI was observed in the composite secondary
ndpoint of MACCE (adjusted HR: 1.64; 95% CI 1.33 to
.03; p  0.0001), exclusively driven by the lower need of
TVR (adjusted HR: 3.51; 95% CI 2.40 to 5.13; p 0.0001)
and TLR (adjusted HR: 2.65; 95% CI 1.73 to 4.04; p 
0.0001). In addition, after propensity score matching was
performed for the entire population, no difference in the
primary study endpoint of death, CVA, and MI was
confirmed (HR: 0.99; 95% CI 0.73 to 1.33; p  0.97).
Similarly, there remained an advantage of CABG in the
composite endpoint of MACCE driven by repeated revas-
cularizations. The lower need for revascularization in this
group suggests that at least “first generation” DES (exclu-
sively used in this preliminary phase of our experience from
2002 to 2006) are still an imperfect solution, unable to
completely eliminate restenosis in complex settings, such as
bifurcation lesions and multivessel disease. It is important to
underline that the higher incidence of TVR in the PCI
group did not translate into a higher incidence of the “hard
endpoints” like death, MI, or CVA. In our opinion, the
need for repeated revascularization should not be considered
only as the “Achilles’ heel” of the technique but also as a
characteristic that does not have any impact on hard
endpoints and can be easily repeated as compared with the
need for repeated CABG. It might be fair to point out that
routine angiographic follow-up was part of this initial
protocol to detect early left main in-stent restenosis and that
many TLR and TVR were angiographically rather than
clinically driven. The low rate of IVUS guidance (33.1%) aswell as the lack of properly sized post-dilation could clearly
have played an important role in the occurrence of TLR in
the PCI group. Moreover, the need for “two stent tech-
niques” as intention-to-treat in 43.1% of the patients is a
measure of the high incidence of complex distal bifurcation
lesions in our registry and could help to explain the overall
10.0% TLR rate in the PCI group.
In our study, there was a significant difference in SYNTAX
scores between the PCI and CABG groups (28.6 14.3 vs.
8.9  13.2, respectively; p  0.01). Interestingly, in such
experienced centers, the extent of coronary artery disease
guided the choice of the treatment even before the intro-
duction of the SYNTAX score, with the SYNTAX trial
that reported worse clinical outcome in the subgroup of
patients with a score 33. Clearly, the application of the
SYNTAX score gives credibility to our practice, helping the
operator and referring physician to decide upon the optimal
therapeutic option in this subset of patients.
From a safety perspective, the overall and cardiac mor-
tality (14.1% vs. 11.4% and 7.5% vs. 6.8% in PCI and
CABG, respectively) are quite reassuring, considering the
high-risk profile of the patients included in the analysis.
Age, SYNTAX score, LVEF, acute MI, and the need for
IABP were all correlated with mortality in multivariable
analysis.
In addition, the rate of definite ST was 1.06%, a value
comparable to previous series. In our registry, the informa-
tion on symptomatic graft occlusion in the CABG group is
not available; however, if we consider the 2.8% rate reported
in a previous series (13), a 1.6% of definite and/or probable
ST is reassuring.
According to the SYNTAX score (19), also in our study
the incidence of CVA was greater in the CABG group
(Table 3).
Considering these encouraging long-term results and the
technical developments in PCI—“second generation” DES;
higher use of IVUS and fractional flow reserve; new imaging
techniques, such as optimal coherence tomography; assess-
ment of clopidogrel responsiveness and more effective anti-
platelet drugs (prasugrel, ticagrelor) as well as in CABG
(higher percentage of off-pump and no-touch techniques)—
there is now a clear need for a prospective, randomized trial
adequately powered to evaluate the optimal revasculariza-
tion treatment in unprotected ULMCA lesions.
The EXCEL (Evaluation of Xience Prime versus Coro-
nary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization) trial is currently randomizing 2,600 pa-
tients with ULMCA disease and a SYNTAX score of 32
to CABG versus second-generation DES (XIENCE Prime,
Abbott Vascular, Temecula, California). The primary end-
point is the composite incidence of death, MI, or stroke at
a median follow-up duration of 3 years, powered for
sequential noninferiority and superiority testing. Questions
remain unanswered with regard to the need to include
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726revascularization in the primary endpoint and the exclusion
of patients with extensive triple vessel disease, in addition to
left main stenosis.
Study limitations. The major limitation is that this is an
observational study. A propensity score adjustment was
performed to adjust for the differences in baseline clinical
and lesion characteristics between the 2 study groups. In
addition a propensity-score matching was also performed.
Another limitation was that, because of the retrospective
nature of the study, we could not analyze all the baseline
angiography films to calculate the SYNTAX score in all
patients (overall 2,064 of 2,775 films were analyzed). Also,
it was not possible calculate the rate of symptomatic graft
occlusion in the CABG group.
Further limitations are the length of clinical follow-up
and the type of stent used.
We acknowledge that, in our registry, the proportion of
patients undergoing PCI is double that of those undergoing
CABG in this registry. This phenomenon might reflect the
practice of selected high-volume tertiary centers, as the ones
included in our study.
Conclusions
In this large “all-comers” multinational registry evaluating
CABG versus PCI with “first generation” DES, no differ-
ence was observed in the primary endpoint of death, CVA,
and MI, at a median of 1,295 days of clinical follow-up.
Rates of repeat revascularization were still higher among
patients who underwent PCI than among those who un-
derwent CABG. In selected cases and in highly competent
tertiary centers, PCI for ULMCA disease can be considered
a safe and effective procedure, with encouraging results at
long-term follow-up, and might possibly be considered a
feasible alternative to CABG.
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